Prolight Diagnostics shows proof of performance in whole blood
Kurs
+16,67%
Likviditet
1,55 MSEK
Prenumeration
Kalender
| Est. tid* | ||
| 2025-11-27 | 09:50 | Kvartalsrapport 2025-Q3 |
| 2025-08-28 | 09:50 | Kvartalsrapport 2025-Q2 |
| 2025-06-25 | N/A | X-dag ordinarie utdelning PRLD 0.00 SEK |
| 2025-06-24 | N/A | Årsstämma |
| 2025-05-30 | 09:50 | Kvartalsrapport 2025-Q1 |
| 2025-02-28 | - | Bokslutskommuniké 2024 |
| 2024-11-27 | - | Kvartalsrapport 2024-Q3 |
| 2024-08-28 | - | Kvartalsrapport 2024-Q2 |
| 2024-05-27 | - | Årsstämma |
| 2024-05-17 | - | Kvartalsrapport 2024-Q1 |
| 2024-05-15 | - | X-dag ordinarie utdelning PRLD 0.00 SEK |
| 2024-02-21 | - | Bokslutskommuniké 2023 |
| 2023-11-27 | - | Extra Bolagsstämma 2023 |
| 2023-11-27 | - | Kvartalsrapport 2023-Q3 |
| 2023-08-29 | - | Kvartalsrapport 2023-Q2 |
| 2023-05-12 | - | X-dag ordinarie utdelning PRLD 0.00 SEK |
| 2023-05-11 | - | Årsstämma |
| 2023-05-11 | - | Kvartalsrapport 2023-Q1 |
| 2023-02-21 | - | Bokslutskommuniké 2022 |
| 2022-11-30 | - | Kvartalsrapport 2022-Q3 |
| 2022-08-29 | - | Kvartalsrapport 2022-Q2 |
| 2022-08-04 | - | Extra Bolagsstämma 2022 |
| 2022-05-23 | - | X-dag ordinarie utdelning PRLD 0.00 SEK |
| 2022-05-20 | - | Årsstämma |
| 2022-05-20 | - | Kvartalsrapport 2022-Q1 |
| 2022-02-22 | - | Bokslutskommuniké 2021 |
| 2021-11-23 | - | Kvartalsrapport 2021-Q3 |
| 2021-08-31 | - | Kvartalsrapport 2021-Q2 |
| 2021-05-06 | - | X-dag ordinarie utdelning PRLD 0.00 SEK |
| 2021-05-05 | - | Årsstämma |
| 2021-05-05 | - | Kvartalsrapport 2021-Q1 |
| 2021-02-24 | - | Bokslutskommuniké 2020 |
| 2020-11-17 | - | Kvartalsrapport 2020-Q3 |
| 2020-08-28 | - | Kvartalsrapport 2020-Q2 |
| 2020-05-21 | - | X-dag ordinarie utdelning PRLD 0.00 SEK |
| 2020-05-20 | - | Årsstämma |
| 2020-05-14 | - | Kvartalsrapport 2020-Q1 |
| 2020-02-13 | - | Bokslutskommuniké 2019 |
| 2019-11-20 | - | Kvartalsrapport 2019-Q3 |
| 2019-08-28 | - | Kvartalsrapport 2019-Q2 |
| 2019-05-16 | - | Årsstämma |
| 2019-05-16 | - | Kvartalsrapport 2019-Q1 |
| 2019-05-10 | - | X-dag ordinarie utdelning PRLD 0.00 SEK |
| 2018-11-20 | - | Kvartalsrapport 2018-Q3 |
| 2018-08-28 | - | Kvartalsrapport 2018-Q2 |
| 2018-05-17 | - | X-dag ordinarie utdelning PRLD 0.00 SEK |
| 2018-05-16 | - | Årsstämma |
| 2018-05-16 | - | Kvartalsrapport 2018-Q1 |
| 2018-02-14 | - | Bokslutskommuniké 2017 |
| 2017-11-23 | - | Kvartalsrapport 2017-Q3 |
| 2017-08-25 | - | Kvartalsrapport 2017-Q2 |
| 2017-05-22 | - | X-dag ordinarie utdelning PRLD 0.00 SEK |
| 2017-05-19 | - | Årsstämma |
| 2017-05-19 | - | Kvartalsrapport 2017-Q1 |
Beskrivning
| Land | Sverige |
|---|---|
| Lista | Nordic SME Sweden |
| Sektor | Hälsovård |
| Industri | Medicinteknik |
Prolight Diagnostics, developer of the digital point-of-care platform Psyros™, has demonstrated that its single molecule detection system gives equivalent performance in whole blood compared to plasma, without having to separate the cells from the sample.
“This is a very important breakthrough for our single molecule counting technology. We are not aware of any other single molecule counting platform that can function with whole blood. The ability to measure in whole blood, without a cell-separation step, reduces complexity, paving the way for an extremely competitive price level”, said Ulf Bladin, CEO of Prolight.
Prolight’s point-of-care troponin assay is developed to facilitate more rapid rule-in and rule-out of myocardial infarction (MI). The company has now demonstrated the ability to quantitatively measure in the single digit nanogram per litre range in whole blood. Fresh human blood samples were spiked using pooled plasma from patients with known elevated troponin levels post-MI. The troponin concentrations in the blood samples were confirmed by measuring them in parallel on a commercially available high-sensitivity troponin assay.
For further information, please contact:
Prolight Diagnostics AB (publ)
E-mail: info@prolightdx.com
Telephone: +46 73 582 39 87
Website: www.prolightdx.com/en/
About Us
Prolight Diagnostics AB develops innovative Point-of-Care (POC) systems. These are small, portable instruments and disposable cartridges for performing in-vitro diagnostic (IVD) tests from a drop of blood.
We want to offer the foremost POC systems on the market for quick, reliable diagnosis of acute events. Our launch product will be for the measurement of troponin, to aid in the rule-in and rule-out of myocardial infarction.
The company’s share is traded on the NGM Nordic SME marketplace, under the ticker PRLD.